Skip to main content
. 2015 Aug 21;6(29):27427–27439. doi: 10.18632/oncotarget.4861

Figure 2. DAB2IP is sufficient to inhibit tumor growth and metastasis of CRC cells.

Figure 2

A. Effect of DAB2IP KD on subcutaneous tumor growth by MTT assay. B. Local invasion of subcutaneous tumors in DAB2IP KD group and control group. Small scale bars represent 100 μm. C. Images of intestinal and hepatic metastases of mice injected with DAB2IP KD SW480 cells (n = 5), and number of metastatic intestinal or hepatic nodules per mice. Small scale bars represent 200 μm. D. Image of pulmonary metastases of mice injected with DAB2IP KD SW480 cells, and number of metastatic lung nodules per mice. Scale bars represent 500 μm. E. Expression of DAB2IP in liver, intestinal or lung metastatic tumors in mice injected with DAB2IP KD cells and control cells by Western blotting. *P < 0.05.